SPPH.US Spencer Pharmaceutical Inc

Healthcare Biotechnology USA Stocks
- USD
Market cap
-
P/E
-
P/B
0.35x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2010.

Is SPPH.US undervalued?

Graham number

The Graham number of Spencer Pharmaceutical Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spencer Pharmaceutical Inc fundamental analysis

No fundamental analysis for Spencer Pharmaceutical Inc yet.

Spencer Pharmaceutical Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spencer Pharmaceutical Inc

Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America an…

Full company profile